Eli Lilly and Company (LLY)
Summary
LLY Chart
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
Eli Lilly Comes Out As ADA Winner
Eli Lilly reported impressive data from bimagrumab and eloralintide programs, reinforcing its leadership in obesity therapeutics. Results from competitors were either as expected or underwhelming. Favorable commercial trends for tirzepatide and a robust pipeline—including orforglipron and retatrutide—support Lilly's continued market dominance for the next 5-7 years.
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
Eli Lilly and Company Dividends
| LLY 1 month ago | Other | €1.28 Per Share |
| LLY 4 months ago | Other | €1.28 Per Share |
| LLY 7 months ago | Other | €1.11 Per Share |
| LLY 10 months ago | Other | €1.11 Per Share |
| LLY 15 May 2024 | Other | €1.11 Per Share |
Eli Lilly and Company Earnings
| 7 Aug 2025 (In 3 weeks) Date | | 5.57 Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | - Cons. EPS | 4.58 EPS |
| 30 Oct 2024 Date | | - Cons. EPS | 0.98 EPS |
| 8 Aug 2024 Date | | - Cons. EPS | 3.05 EPS |
| LLY 1 month ago | Other | €1.28 Per Share |
| LLY 4 months ago | Other | €1.28 Per Share |
| LLY 7 months ago | Other | €1.11 Per Share |
| LLY 10 months ago | Other | €1.11 Per Share |
| LLY 15 May 2024 | Other | €1.11 Per Share |
| 7 Aug 2025 (In 3 weeks) Date | | 5.57 Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | - Cons. EPS | 4.58 EPS |
| 30 Oct 2024 Date | | - Cons. EPS | 0.98 EPS |
| 8 Aug 2024 Date | | - Cons. EPS | 3.05 EPS |
Eli Lilly and Company (LLY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Eli Lilly and Company ever had a stock split?
Eli Lilly and Company Profile
| Drug Manufacturers - General Industry | Healthcare Sector | David A. Ricks CEO | XETRA Exchange | US5324571083 ISIN |
| US Country | 47,000 Employees | 14 Feb 2025 Last Dividend | 16 Oct 1997 Last Split | 13 Jan 1978 IPO Date |
Overview
Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.
Products and Services
- Diabetes Care
Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.
- Oncology
Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.
- Immunology
Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
- Digestive Diseases
Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.
- Neurological Disorders
Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.
- Other Therapeutic Areas
The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.
Contact Information
